D’Souza et al. tested the effects of the agonists of GPR43 (G-protein coupled receptor 43), one of the SCFA receptors, within the scope of their potential application in the therapy of IBD [147]. This evidence concerns the gene FFAR2 and inflammatory bowel disease.